Central Role of Tumor-Associated CD8+ T Effector/Memory Cells in Restoring Systemic Antitumor Immunity1

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Immunology

• Publication date

  2009-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.0802793PMID 19299720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment

  2008cited by this paper
• Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

  2008cited by this paper
• Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.

  2008cited by this paper
• Tumour immunity: effector response to tumour and role of the microenvironment.

  2008cited by this paper
• Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors.

  2008cited by this paper
• Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease

  2008cited by this paper
• Signaling defects in anti‐tumor T cells

  2008cited by this paper
• Targeting the Effector Site with IFN-αβ-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors1

  2008cited by this paper
• IL-12 Rapidly Alters the Functional Profile of Tumor-Associated and Tumor-Infiltrating Macrophages In Vitro and In Vivo1

  2007cited by this paper
• Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors.

  2007cited by this paper
• Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment

  2007cited by this paper
• The B7 Family and Cancer Therapy: Costimulation and Coinhibition

  2007cited by this paper
• Recent advances and current challenges in tumor immunology and immunotherapy.

  2007cited by this paper
• Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine1

  2007cited by this paper
• IL-12 + GM-CSF Microsphere Therapy Induces Eradication of Advanced Spontaneous Tumors in her-2/neu Transgenic Mice But Fails to Achieve Long-Term Cure Due to the Inability to Maintain Effector T-Cell Activity

  2006cited by this paper
• Reversing Tumor Immune Suppression with Intratumoral IL-12: Activation of Tumor-Associated T Effector/Memory Cells, Induction of T Suppressor Apoptosis, and Infiltration of CD8+ T Effectors1

  2006cited by this paper
• Chronic Immune Therapy Induces a Progressive Increase in Intratumoral T Suppressor Activity and a Concurrent Loss of Tumor-Specific CD8+ T Effectors in her-2/neu Transgenic Mice Bearing Advanced Spontaneous Tumors1

  2006cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Recent developments in the transcriptional regulation of cytolytic effector cells

  2004cited by this paper
• Reflections on CD8 T-cell activation and memory

  2004cited by this paper
• On the role of APC-activation for in vitro versus in vivo T cell priming.

  2003cited by this paper
• Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-γ1

  2003cited by this paper
• Programmed contraction of CD8+ T cells after infection

  2002cited by this paper
• What messenger RNA capping tells us about eukaryotic evolution

  2002cited by this paper
• Interleukin-12 in anti-tumor immunity and immunotherapy.

  2002cited by this paper
• Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.

  2002cited by this paper
• A critical role for IL‐12 in CCR5 induction on T cell receptor‐triggered mouse CD4+ and CD8+ T cells

  2001cited by this paper
• CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis

  2001cited by this paper
• In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

  2000cited by this paper
• Cellular responses to interferon-gamma.

  1997cited by this paper
• CD8(+) T cell-mediated spontaneous diabetes in neonatal mice.

  1996cited by this paper
• The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor‐infiltrating lymphocytes

  1994cited by this paper
• Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.

  1991cited by this paper

• Enhancing the Antitumor Effect of MUC16 CART Cells in Ovarian Cancer: The Potential of Oncolytic Adenovirus.

  2025cites this paper
• Discovery of an theranostic functional mAb for visualizing the sensitivity and effectiveness of PD-L1 checkpoint therapy.

  2024cites this paper
• Unraveling the Heterogeneity of Tumor Immune Microenvironment in Hepatocellular Carcinoma by Single-Cell RNA Sequencing and its Implications for Prognosis and Therapeutic Response

  2024cites this paper
• Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors.

  2024cites this paper
• Anti-tumor immune potentiation targets-engineered nanobiotechnologies: Design principles and applications

  2023cites this paper
• Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment

  2023cites this paper
• Cancer Cell‐targeted and Activatable Photoimmunotherapy Spares T Cells in a 3D Coculture Model

  2020cites this paper
• Cytokine-Encapsulated Biodegradable Microspheres for Immune Therapy

  2020cites this paper
• Localized Interleukin-12 for Cancer Immunotherapy

  2020cites this paper
• High Endothelial Venule with Concomitant High CD8+ Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer

  2020cites this paper
• A Prognostic Immunoscore for Relapse-Free Survival Prediction in Colorectal Cancer

  2020cites this paper
• Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells

  2019cites this paper
• Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.

  2019cites this paper
• Follicular helper T cells promote the effector functions of CD8+ T cells via the provision of IL‐21, which is downregulated due to PD‐1/PD‐L1‐mediated suppression in colorectal cancer

  2018cites this paper
• Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth

  2018cites this paper
• Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8+ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma

  2018cites this paper
• Multifaceted Role of Neuropilins in the Immune System: Potential Targets for Immunotherapy

  2017cites this paper
• Neem leaf glycoprotein generates superior tumor specific central memory CD8+ T cells than cyclophosphamide that averts post-surgery solid sarcoma recurrence.

  2017cites this paper
• CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation

  2017cites this paper
• Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity

  2017cites this paper
• Interleukin 2 and interleukin 10 function synergistically to promote CD8+ T cell cytotoxicity, which is suppressed by regulatory T cells in breast cancer

  2017cites this paper
• Cancer Immunotherapy: Cancer Vaccines

  2017cites this paper
• Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer

  2016cites this paper
• Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy

  2016cites this paper
• Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC)

  2015cites this paper
• Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints

  2015cites this paper
• Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis in gastric cancer

  2015cites this paper
• Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death

  2015cites this paper
• This information is current as Peripheral Regulatory T Cells Tumors Is Driven by Uncommitted Treated − Regulatory Rebound in IL-12

  2015cites this paper
• Emerging Strategies for Cancer Immunoprevention

  2015cites this paper
• Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

  2015cites this paper
• Regulatory Rebound in IL-12–Treated Tumors Is Driven by Uncommitted Peripheral Regulatory T Cells

  2015cites this paper
• Targeting T Cells for the Immune-Modulation of Human Diseases

  2015cites this paper
• Tumor Induces the Expansion of Foxp3+CD25high and CD11b+Gr-1+ Cell Population in the Early Phase of Tumor Progression

  2015cites this paper
• Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis

  2014cites this paper
• Immature Myeloid Cells Promote Tumor Formation Via Non-Suppressive Mechanism

  2014cites this paper
• Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.

  2014cites this paper
• MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

  2014cites this paper
• GenePattern flow cytometry suite

  2013cites this paper
• IGHV1-69 as a promising candidate for the development of a shared immunotherapy to B-cell lymphomas

  2013cites this paper
• Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity.

  2013cites this paper
• Decitabine and Vorinostat Cooperate To Sensitize Colon Carcinoma Cells to Fas Ligand-Induced Apoptosis In Vitro and Tumor Suppression In Vivo

  2012cites this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cites this paper
• Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance.

  2012cites this paper
• Characterization of iNOS+ Neutrophil-like ring cell in tumor-bearing mice

  2012cites this paper
• Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity

  2012cites this paper
• Nitric oxide short-circuits interleukin-12-mediated tumor regression

  2011cites this paper
• Chronic Chemoimmunotherapy Achieves Cure of Spontaneous Murine Mammary Tumors via Persistent Blockade of Posttherapy Counter-Regulation

  2011cites this paper
• Dichotomous Effects of IFN-γ on Dendritic Cell Function Determine the Extent of IL-12–Driven Antitumor T Cell Immunity

  2011cites this paper
• Posttherapy Counter-Regulation Tumors via Persistent Blockade of Cure of Spontaneous Murine Mammary Chronic Chemoimmunotherapy Achieves

  2011cites this paper
• From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors

  2011cites this paper
• A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

  2011cites this paper
• Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity.

  2010cites this paper
• Liposomes targeting tumour stromal cells

  2010cites this paper
• Tumor-Resident CD8+ T-cell: The Critical Catalyst in IL-12-Mediated Reversal of Tumor Immune Suppression

  2010cites this paper
• Activated CD8+ T-Effector/Memory Cells Eliminate CD4+ CD25+ Foxp3+ T-Suppressor Cells from Tumors via FasL Mediated Apoptosis1

  2009cites this paper
• Mediated Apoptosis T-Suppressor Cells from Tumors via FasL + Foxp3 + CD25 + Eliminate CD4 T-Effector/Memory Cells + Activated CD8

  2009cites this paper
• Tumor Suppression in Vivo Ligand-induced Apoptosis in Vitro and Sensitize Colon Carcinoma Cells to Fas Decitabine and Vorinostat Cooperate To

  year unknowncites this paper